Valuation: Biogen Inc.

Market Cap 37.61B 58,140B 33.52B 30.66B 27.92B 52.63B 3,555B 54.05B 368B 147B 1,882B 141B 138B 5,940B P/E 2026 *
45.6x
P/E 2027 * 21.9x
Enterprise Value 43.25B 66,850B 38.54B 35.25B 32.1B 60.51B 4,087B 62.14B 423B 169B 2,164B 162B 159B 6,830B EV / Sales 2026 *
4.11x
EV / Sales 2027 * 3.78x
Free-Float
85.81%
Yield 2026 *
-
Yield 2027 * -
1 day+2.69%
1 week+5.32%
Current month+1.17%
1 month+19.68%
3 months+28.89%
6 months+52.89%
Current year+58.34%
1 week 31,640
Extreme 31640
33,100
1 month 26,800
Extreme 26800
33,100
Current year 18,640
Extreme 18640
33,100
1 year 17,360
Extreme 17360
33,100
3 years 9,930
Extreme 9930
33,100
5 years 2,789.5
Extreme 2789.5
33,100
10 years 737
Extreme 737
33,100
Manager TitleAgeSince
Chief Executive Officer 66 13/11/2022
Director of Finance/CFO 60 28/02/2025
Chief Tech/Sci/R&D Officer - 27/10/2024
Director TitleAgeSince
Director/Board Member 69 22/03/2010
Director/Board Member 77 31/12/2009
Director/Board Member 72 18/06/2019
Change 5-day change 1-year change 3-year change Capi.($)
+2.69%+5.32% - - 37.61B
-3.76%+5.93%+50.49%+140.35% 1,263B
-1.45%+0.47%+45.73%+79.94% 665B
-2.24%+0.79%+33.51%+103.82% 521B
-1.06%-1.78%+48.37%+65.10% 387B
-2.27%+4.26%+75.22%+42.14% 371B
-0.10%+3.79%+32.16%+60.93% 310B
+0.13%+10.01%+12.08%+36.73% 293B
-3.80%+1.87%+55.13%+70.56% 259B
-3.96%+5.26%+36.24%+105.38% 216B
Average -1.24%+5.59%+43.22%+78.33% 476.15B
Weighted average by Cap. -1.93%+5.96%+45.25%+92.43%

Financials

2026 *2027 *
Net sales 10.53B 16,275B 9.38B 8.58B 7.82B 14.73B 995B 15.13B 103B 41.23B 527B 39.52B 38.67B 1,663B 10.76B 16,637B 9.59B 8.77B 7.99B 15.06B 1,017B 15.47B 105B 42.14B 539B 40.4B 39.53B 1,700B
Net income 788M 1,218B 702M 642M 585M 1.1B 74.47B 1.13B 7.72B 3.09B 39.44B 2.96B 2.89B 124B 1.79B 2,761B 1.59B 1.46B 1.33B 2.5B 169B 2.57B 17.49B 7B 89.41B 6.71B 6.56B 282B
Net Debt 5.63B 8,709B 5.02B 4.59B 4.18B 7.88B 532B 8.1B 55.17B 22.06B 282B 21.15B 20.69B 890B 3.08B 4,762B 2.75B 2.51B 2.29B 4.31B 291B 4.43B 30.17B 12.06B 154B 11.56B 11.32B 487B
Projected Income Statement - Annual - Biogen Inc.
Logo Biogen Inc.
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows: - sales of medicines (72%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.; - royalties (7.4%) ; - other (20.6%): primarily revenues from partnership agreements.
Employees
7,500
Date Price Change Volume
05/11/26 ARS 31,260.00 -4.81% 3,999
04/11/26 ARS 32,840.00 +2.69% 383
03/11/26 ARS 31,980.00 +0.95% 173
02/11/26 ARS 31,680.00 -2.40% 301
30/10/26 ARS 32,460.00 +2.40% 1,842
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Biogen Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
36
Last Close Price
254.46USD
Average target price
264.82USD
Spread / Average Target
+4.07%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Biogen Inc.